View Older Stories View More Recent Stories

Feb 23, 2023 08:00AM New Data Suggest UPLIZNA® (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Did Not Increase the Risk of COVID-19 Infection or Reduce Antibody Levels From Childh
Feb 14, 2023 05:20AM Soros buys Horizon Therapeutics, First Horizon, adds to Alphabet, cuts Amazon
Jan 30, 2023 08:00AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2022 Financial Results on March 1, 2023
Jan 18, 2023 08:03AM Horizon Therapeutics (HZNP) Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population
Jan 18, 2023 08:00AM Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population; Only Phase 2 Trial to Meet Pri
Jan 4, 2023 08:01AM Horizon Therapeutics (HZNP) enrolls first patient in Phase 2 of daxdilimab to treat DLE
Jan 4, 2023 08:00AM Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus
Dec 20, 2022 08:02AM Horizon Therapeutics (HZNP) Grated Approval for UPLIZNA in Brazil
Dec 20, 2022 08:00AM UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Dec 8, 2022 08:04AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) enrolls first patient in HZN-457 phase 1 trial for gout
Dec 8, 2022 08:00AM Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Dec 8, 2022 08:00AM Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Nov 23, 2022 06:03AM Xeris (XERS) Enters Research Collaboration and Option Agreement With Horizon (HZNP) for XeriJect Formulation of Teprotumumab
Nov 23, 2022 06:00AM Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab
Nov 16, 2022 08:15AM Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
Nov 16, 2022 08:11AM Horizon Therapeutics (HZNP) Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
Nov 16, 2022 08:00AM Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
Nov 10, 2022 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
Nov 8, 2022 10:01AM Horizon Therapeutics (HZNP) Announces Sustained Patient Response to KRYSTEXXA Injection with Methotrexate Compared to KRYSTEXXA Alone
Nov 8, 2022 10:00AM Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
Nov 7, 2022 05:39AM Horizon Therapeutics (HZNP) Reports New Strong Data on KRYSTEXXA
Nov 5, 2022 10:00AM Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
Nov 2, 2022 07:00AM Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectatio
Nov 1, 2022 09:00AM Horizon Therapeutics plc Named to the Seramount Inclusion Index
Oct 27, 2022 08:30AM Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
Oct 27, 2022 08:30AM Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
Oct 26, 2022 08:00AM Horizon Therapeutics (HZNP) Reports New Strong Data of UPLIZNA Phase 3 Trial Data
Oct 26, 2022 08:00AM New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks
Oct 24, 2022 05:58AM Horizon Therapeutics (HZNP) Reports Strong New Real-World Analysis of TEPEZZA
Oct 22, 2022 10:30AM New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment
Oct 13, 2022 08:00AM Horizon Therapeutics plc to Present New Data on TEPEZZA® (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) Annual Meeting
Oct 12, 2022 08:00AM Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2022
Oct 6, 2022 10:03AM Horizon Therapeutics plc Named to Newsweek’s 2022 Top 100 Most Loved Workplaces
Oct 6, 2022 08:00AM Horizon Therapeutics plc to Release Third-Quarter 2022 Financial Results and Host Webcast on Nov. 2, 2022
Oct 2, 2022 11:15AM New Data Reveal Molecular Drivers of Thyroid Eye Disease (TED) May Remain Activated In Patients with Low Clinical Activity Score (CAS)
Sep 29, 2022 08:00AM Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Sep 22, 2022 08:04AM Horizon Therapeutics plc Expands Commitment to Education Equity, STEAM Careers and Historically Black Colleges and Universities, Adding Meharry Medical College as Horizon Scholars Partner
Sep 21, 2022 08:04AM Horizon Therapeutics plc Announces EB Research Partnership Receives 2022 Horizon Prize, Powered by MIT Solve
Sep 19, 2022 08:00AM Horizon to Highlight Novel Insights in Gout Care During the American College of Rheumatology Convergence 2022
Sep 16, 2022 09:00AM Horizon Therapeutics plc Makes Founding Gift to Support the University of Notre Dame’s Patient Advocacy Initiative
Sep 14, 2022 08:00AM Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology
Sep 13, 2022 08:30AM Horizon Therapeutics plc Joins the International Agency for the Prevention of Blindness (IAPB) to Encourage People to #LoveYourEyes this World Sight Day
Sep 12, 2022 08:00AM Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint
Sep 9, 2022 08:00AM Horizon Therapeutics (HZNP) Announces $500 Million Share Repurchase Program
Sep 9, 2022 08:00AM Horizon Therapeutics plc Announces $500 Million Share Repurchase Program
Sep 8, 2022 08:03AM Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2022 List
Aug 31, 2022 09:03AM Horizon Therapeutics plc Named One of PEOPLE’s 100 Companies That Care®
Aug 29, 2022 04:00AM Horizon Therapeutics plc Announces Plans to Expand its Development and Manufacturing Facility in Waterford, Ireland
Aug 25, 2022 08:00AM Horizon Therapeutics plc to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 15, 2022 08:14AM Q32 Bio and Horizon Therapeutics (HZNP) Announce Collaboration in Autoimmune Diseases
View More Recent Stories View Older Stories